Clinical Impact of New Data From CROI 2017
Source: 2017 Conference on Retroviruses and Opportunistic Infections*

Slideset

Clinical Impact of New Data From CROI 2017

Expert faculty members Joel E. Gallant, MD, MPH, and Charles B. Hicks, MD, summarize key studies from this important annual conference.
Format: Microsoft PowerPoint (.ppt)
File size: 1.25 MB
Date posted: 3/3/2017
  • How New Data From CROI 2017 May Inform Switch Strategies in HIV-Infected Patients With Poor Bone Health

    Charles B. Hicks MD - 4/21/2017    
    Is switching TDF to TAF justified in osteopenic women?
  • Optimal ART During Late Pregnancy After a Break in Therapy

    Kathleen E. Squires MD - 4/20/2017    
    Which regimen may work best during the third trimester?
  • How New Data From CROI 2017 May Inform Treatment Simplification Options

    Charles B. Hicks MD - 4/20/2017    
    Is the switch to a 2-drug regimen in virologically suppressed HIV-infected patients feasible?
  • The Promise of Long-Acting Injectable Antiretroviral Therapies

    Paul E. Sax MD - 4/12/2017    
    Will long-acting cabotegravir plus rilpivirine injections satisfy patient desire for less frequent dosing? Here is my take.
  • How New Data From CROI 2017 May Renew Interest in NNRTIs

    Charles B. Hicks MD - 4/21/2017    
    How do phase III data on doravirine affect the potential for future therapy with NNRTIs?